On heels of trial readout, Frequency out-licenses hearing loss therapy to Astellas

Frequency has found a partner in Astellas for its regenerative therapy to treat hearing loss in a deal that will support development of FX-322 as it moves into Phase

Read the full 295 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE